BIRC5 and cancer: Moreover, considering that the presence of autoantibody against BIRC5 likely reflects the immune response targeting BIRC5 antigen, it is suggested that BIRC5 autoantibody-positive cancers with a poor prognosis may exhibit a higher likelihood of favorable responses to immune checkpoint inhibitors.